{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:06:34Z","timestamp":1761887194435,"version":"build-2065373602"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.nrleng.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T11:24:52Z","timestamp":1622287492000},"page":"451-461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination"],"prefix":"10.1016","volume":"36","member":"78","reference":[{"author":"World Health Organization","key":"10.1016\/j.nrleng.2021.05.001_bib0005"},{"author":"European Centre for Disease Prevention and Control","key":"10.1016\/j.nrleng.2021.05.001_bib0010"},{"author":"Ministerio de Ciencia e Innovaci\u00f3n","key":"10.1016\/j.nrleng.2021.05.001_bib0015"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 \u2014 interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0025","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 \u2014 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0030","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0035","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0040","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0050","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0060","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0065","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"year":"2021","series-title":"Red Nacional de Vigilancia Epidemiol\u00f3gica. Informe no 74. Situaci\u00f3n de COVID-19 en Espa\u00f1a. Casos diagnosticados a partir 10 de mayo. Informe COVID-19","author":"Instituto de Salud Carlos III","key":"10.1016\/j.nrleng.2021.05.001_bib0070"},{"author":"European Medicines Agency","key":"10.1016\/j.nrleng.2021.05.001_bib0075"},{"author":"European Medicines Agency","key":"10.1016\/j.nrleng.2021.05.001_bib0080"},{"author":"European Medicines Agency","key":"10.1016\/j.nrleng.2021.05.001_bib0085"},{"author":"Federaci\u00f3n de Asociaciones Cient\u00edfico M\u00e9dicas Espa\u00f1olas","key":"10.1016\/j.nrleng.2021.05.001_bib0090"},{"author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","key":"10.1016\/j.nrleng.2021.05.001_bib0095"},{"author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","key":"10.1016\/j.nrleng.2021.05.001_bib0100"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0105","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMcp1411910","article-title":"Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0110","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"Greinacher","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/hum.2007.0051","article-title":"Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia","volume":"18","author":"Hofherr","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0120","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/(SICI)1521-2254(199909\/10)1:5<360::AID-JGM54>3.0.CO;2-Q","article-title":"Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits","volume":"1","author":"Cichon","year":"1999","journal-title":"J Gene Med"},{"issue":"5 Pt 1","key":"10.1016\/j.nrleng.2021.05.001_bib0125","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/mthe.2001.0330","article-title":"Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors","volume":"3","author":"Schnell","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0130","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1046\/j.1365-2141.2003.04719.x","article-title":"Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance","volume":"123","author":"Wolins","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.gt.3302347","article-title":"Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice","volume":"12","author":"Varnavski","year":"2005","journal-title":"Gene Ther"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0140","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0145","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0150","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021011958","article-title":"Prothrombotic immune thrombocytopenia after COVID-19 vaccine","author":"Tiede","year":"2021","journal-title":"Blood"},{"author":"Brighton Collaboration","key":"10.1016\/j.nrleng.2021.05.001_bib0155"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0160","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15346","article-title":"Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)","author":"Thaler","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0165","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"author":"British Society of Haemotology","key":"10.1016\/j.nrleng.2021.05.001_bib0170"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000111256","article-title":"Anatomy of cerebral veins and sinuses","volume":"23","author":"Kili\u00e7","year":"2008","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0180","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0333102417698707","article-title":"Headache in cerebral venous sinus thrombosis revisited: Exploring the role of vascular congestion and cortical vein thrombosis","volume":"38","author":"Singh","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10194-010-0186-3","article-title":"Headache in Cerebral Venous Thrombosis: incidence, pattern and location in 200 consecutive patients","volume":"11","author":"Wasay","year":"2010","journal-title":"J Headache Pain"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0190","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020900","article-title":"Presence of red flags in patients with cerebral venous sinus thrombosis admitted to the emergency department because of headache: A STROBE compliant cohort-study","volume":"99","author":"Garc\u00eda-Azor\u00edn","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11916-019-0786-9","article-title":"Cerebral venous thrombosis headache","volume":"23","author":"Mehta","year":"2019","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0200","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrneurol.2017.104","article-title":"Cerebral venous thrombosis","volume":"13","author":"Silvis","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.nrleng.2021.05.001_bib0205","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3174\/ajnr.A1451","article-title":"Noncontrast CT in deep cerebral venous thrombosis and sinus thrombosis: comparison of its diagnostic value for both entities","volume":"30","author":"Linn","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0210","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/WNL.0000000000006959","article-title":"Diagnostic accuracy of noncontrast CT imaging markers in cerebral venous thrombosis","volume":"92","author":"Buyck","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0215","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11547-020-01263-2","article-title":"Accuracy of unenhanced CT in the diagnosis of cerebral venous sinus thrombosis","volume":"126","author":"Bonatti","year":"2021","journal-title":"Radiol Med"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0220","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41598-020-57867-1","article-title":"Diagnostic value of non-contrast brain computed tomography in the evaluation of acute cerebral venous thrombosis","volume":"10","author":"Tayyebi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0225","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1055\/s-0038-1642636","article-title":"The performance of CT versus MRI in the differential diagnosis of cerebral venous thrombosis","volume":"118","author":"Xu","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2018.05.012","article-title":"Accuracy of magnetic resonance venography in diagnosing cerebral venous sinus thrombosis","volume":"167","author":"Gao","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0235","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000478980","article-title":"Venous stasis and cerebrovascular complications in cerebral venous sinus thrombosis","volume":"78","author":"Sato","year":"2017","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0240","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11910-013-0417-5","article-title":"Diagnosis and treatment of cerebral venous and sinus thrombosis","volume":"14","author":"Weimar","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0245","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11910-019-0988-x","article-title":"Cerebral venous thrombosis: an update","volume":"19","author":"Ferro","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0250","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia After Ad26.COV2.S vaccination, March 2 to April 21, 2021","author":"See","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.medcli.2018.11.002","article-title":"Cerebral venous thrombosis following treatment with intravenous immunoglobulin","volume":"153","author":"Sancho Salda\u00f1a","year":"2019","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0260","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/ijccm.IJCCM_512_17","article-title":"Cerebral venous thrombosis after intravenous immunoglobulin therapy in immune thrombocytopenic purpura","volume":"22","author":"Al-Mendalawi","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0265","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrneurol.2017.143","article-title":"Stroke: patients with CVT urgently need high-quality evidence","volume":"13","author":"Riva","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0270","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1468-1331.2010.03011.x","article-title":"European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients","volume":"17","author":"Einh\u00e4upl","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0275","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/STR.0b013e31820a8364","article-title":"American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Saposnik","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0280","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/2396987317719364","article-title":"European Stroke Organization. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis \u2014 endorsed by the European Academy of Neurology","volume":"2","author":"Ferro","year":"2017","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0285","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0140-6736(91)90607-Q","article-title":"Heparin treatment in sinus venous thrombosis","volume":"338","author":"Einh\u00e4upl","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0290","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000067117","article-title":"Heparin treatment in cerebral sinus and venous thrombosis: patients at risk of fatal outcome","volume":"15","author":"Mehraein","year":"2003","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0295","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/ene.13064","article-title":"Outcome of heparin-treated patients with acute cerebral venous sinus thrombosis: influence of the temporal pattern of intracerebral haemorrhage","volume":"23","author":"Busch","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0300","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1161\/STROKEAHA.110.588822","article-title":"ISCVT Investigators. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis","volume":"41","author":"Coutinho","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0305","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1468-1331.2012.03690.x","article-title":"Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial","volume":"19","author":"Misra","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0310","doi-asserted-by":"crossref","first-page":"357","DOI":"10.17712\/nsj.2015.4.20150375","article-title":"The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis","volume":"20","author":"Afshari","year":"2015","journal-title":"Neurosciences (Riyadh)"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amsu.2017.03.016","article-title":"Low molecular weight heparin versus unfractionated heparin in the management of cerebral venous thrombosis: a systematic review and meta-analysis","volume":"17","author":"Qureshi","year":"2017","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0320","article-title":"Diagnosis and managmenentof cerebral venous sinus thrombosis with vaccine-induced thrombotic thrombocytopenia","author":"American Heart Association\/American Stroke AssociationStroke Council Leadership","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0325","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2004.11.006","article-title":"Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia","volume":"116","author":"Matthai","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0330","doi-asserted-by":"crossref","DOI":"10.1007\/s11096-021-01260-z","article-title":"Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis","author":"Colarossi","year":"2021","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0335","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/NRL.0000000000000146","article-title":"Cerebral venous sinus thrombosis due to low-molecular-weight heparin-induced thrombocytopenia","volume":"22","author":"Gleichgerrcht","year":"2017","journal-title":"Neurologist"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0340","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/STROKEAHA.111.625574","article-title":"The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study","volume":"43","author":"Barreto","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0345","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/STROKEAHA.117.016720","article-title":"ARTSS-2 Investigators. Randomized, multicenter trial of ARTSS-2 (Argatroban with recombinant tissue plasminogen activator for acute stroke)","volume":"48","author":"Barreto","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0350","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.08.036","article-title":"Safety and feasibility of argatroban, recombinant tissue plasminogen activator, and intra-arterial therapy in stroke (ARTSS-IA Study)","volume":"27","author":"Berekashvili","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","key":"10.1016\/j.nrleng.2021.05.001_bib0355"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0360","first-page":"1","article-title":"Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty","author":"Hwang","year":"2020","journal-title":"Platelets"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0365","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12185-017-2271-8","article-title":"Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis","volume":"106","author":"Sun","year":"2017","journal-title":"Int J Hematol"},{"author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","key":"10.1016\/j.nrleng.2021.05.001_bib0370"},{"author":"Agencia Espa\u02dcnola de Medicamentos y Productos Sanitarios","key":"10.1016\/j.nrleng.2021.05.001_bib0375"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0380","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.3748\/wjg.14.4576","article-title":"Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis","volume":"14","author":"Thorsteinsson","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0385","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10245330500093492","article-title":"Fondaparinux: a potential new therapy for HIT","volume":"10","author":"Kuo","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0390","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clineuro.2018.10.015","article-title":"Is it safe to treat cerebral venous thrombosis with oral rivaroxaban without heparin? A preliminary study from 20 patients","volume":"175","author":"Shankar Iyer","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0395","first-page":"e4589","article-title":"The role of warfarin and rivaroxaban in the treatment of cerebral venous thrombosis","volume":"11","author":"Fayyaz","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21556660.2020.1838769","article-title":"Use of oral rivaroxaban in cerebral venous thrombosis","volume":"10","author":"Maqsood","year":"2020","journal-title":"J Drug Assess"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0405","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1182\/bloodadvances.2020003244","article-title":"Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)","volume":"4","author":"Connor","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0410","first-page":"e13663","article-title":"An observational study to evaluate the effectiveness of rivaroxaban in the management of cerebral venous sinus thrombosis","volume":"13","author":"Fatima","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0415","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12883-021-02091-1","article-title":"Rivaroxaban for the treatment of cerebral venous thrombosis","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.nrleng.2021.05.001_bib0420","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2018.11.018","article-title":"Apixaban and rivaroxaban in patients with cerebral venous thrombosis","volume":"173","author":"Covut","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0425","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jns.2017.09.007","article-title":"Apixaban for the treatment of cerebral venous thrombosis: a case series","volume":"381","author":"Rao","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0430","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.597623","article-title":"Comparison of novel oral anticoagulants and vitamin k antagonists in patients with cerebral venous sinus thrombosis on efficacy and safety: a systematic review","volume":"11","author":"Li","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0435","doi-asserted-by":"crossref","first-page":"e040212","DOI":"10.1136\/bmjopen-2020-040212","article-title":"Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review","volume":"11","author":"Bose","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0440","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/rth2.12480","article-title":"Direct oral anticoagulants for unusual-site venous thromboembolism","volume":"5","author":"Riva","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0445","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/rth2.12424","article-title":"Anticoagulation in splanchnic and cerebral vein thrombosis: an international vignette-based survey","volume":"4","author":"Riva","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.nrleng.2021.05.001_bib0450","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/STROKEAHA.107.502658","article-title":"Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study","volume":"39","author":"Stam","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0455","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005480","article-title":"Epidemiology, endovascular treatment, and prognosis of cerebral venous thrombosis: US Center Study of 152 Patients","volume":"6","author":"Salottolo","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0460","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1038\/s41598-020-61884-5","article-title":"Endovascular mechanical thrombectomy and on-site chemical thrombolysis for severe cerebral venous sinus thrombosis","volume":"10","author":"Liao","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0465","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/3-211-27911-3_28","article-title":"Decompressive craniectomy in severe cerebral venous and dural sinus thrombosis","volume":"94","author":"Keller","year":"2005","journal-title":"Acta Neurochir Suppl"},{"key":"10.1016\/j.nrleng.2021.05.001_bib0470","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/jcm9030743","article-title":"Cerebral and splanchnic vein thrombosis: advances, challenges, and unanswered questions","volume":"9","author":"Riva","year":"2020","journal-title":"J Clin Med"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580821000754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580821000754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:32:08Z","timestamp":1761881528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580821000754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2173580821000754"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2021.05.001","relation":{},"ISSN":["2173-5808"],"issn-type":[{"type":"print","value":"2173-5808"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2021.05.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}